Skip to content

The Safety and Efficacy of SeQuent® Please in Real World Chinese Coronary Instent Restenosis Patients

To Evaluate the Long Term Safety and Efficacy of Drug Coated Balloon SeQuent® Please in Chinese Coronary Instent Restenosis Patients,a Prospective, Multi-center,Randomization Clinical Trial.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03624205
Enrollment
520
Registered
2018-08-10
Start date
2015-04-24
Completion date
2022-03-01
Last updated
2018-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary In Sentrestenosis

Brief summary

The purpose of this study is to evaluate the efficacy and safety of paclitaxel -eluting PTCA- balloon (SeQuent® Please) in real world Chinese Coronary In Sentrestenosis patients

Interventions

DEVICEpaclitaxel-releasing coronary balloon (SeQuent® Please)

SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial

Sponsors

B. Braun Medical International Trading Company Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

Criteria related to subjects * At the age of 18-80, Both male and female; * Patients with coronary In sentrestenosis and suitable for the theory of Drug Eluting PTCA Balloon Catheter(SeQuent® Please), no more than 1 target lesion in each coronary artery * After pre-dilation of target lesion, the residual stenosis is ≥ 30% , patients with type B dissection * Patients must agree to sign the ICF and to undergo the clinical follow-up at 30 days, 6 months, 6 months, 12 months, 24 months, 36months, 48 months and 60 months after operation Criteria related to lesions * The target lesion length and target vessel diameter should be consistent with the instructions of Drug Eluting PTCA Balloon Catheter(SeQuent® Please)

Exclusion criteria

Criteria related to subjects * Women with pregnancy or lactation * Patient with cardiac shock * Patients with Hemorrhagic physique or active gastrointestinal ulcers, with cerebral apoplexy or transient cerebral ischemia within 3 months, who couldn't be tolerated the expected aspirin and/or clopidogrel theory * Patients with severe valvular heart disease * Patients with severe congestive heart failure or NYHA class IV heart failure; * Patients who have received heart transplant; * Patients with life expectancy more than 60 months, or those who is difficulties in clinical follow-up. * Patients who are currently involved in any other clinical trial; * Patients that the investigators think that those are not suitable Criteria related to lesions * Chronic total occlusion * Lesion that cannot be treated with PTCA or other interventional techniques; * The vessel diameter \< 2.25 mm * Left main disease needed to be treated

Design outcomes

Primary

MeasureTime frameDescription
Target Lesion Failure in 12 months after operation1 yearTo measure Target Lesion Failure in 12 months by using angiography

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026